Baricitinib Demonstrates Superiority to Adalimumab in Improving Signs and Symptoms of Rheumatoid Arthritis in Pivotal Phase 3 Study
Go back to Baricitinib Demonstrates Superiority to Adalimumab in Improving Signs and Symptoms of Rheumatoid Arthritis in Pivotal Phase 3 Study| Incyte Genomics, Inc. (NASDAQ: INCY) | Delayed: 126.75 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $126.75 | 52 Week High | $118.49 | |||
| Open | $126.75 | 52 Week Low | $55.00 | |||
| Day High | $126.75 | P/E | N/A | |||
| Day Low | $126.75 | EPS | $-0.56 | |||
| Volume | 45 | |||||
| Lilly (Eli) & Co. (NYSE: LLY) | Delayed: 1149.36 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1149.36 | 52 Week High | $88.16 | |||
| Open | $1149.36 | 52 Week Low | $67.88 | |||
| Day High | $1149.36 | P/E | 266.06 | |||
| Day Low | $1149.36 | EPS | $4.32 | |||
| Volume | 6,078 | |||||
